Core Viewpoint - SelectQuote Inc. is under increased legal scrutiny following a whistleblower lawsuit alleging deceptive sales practices, leading to a significant drop in its stock price and a subsequent class-action lawsuit from investors [1][4]. Legal Issues - The U.S. Department of Justice (DOJ) has intervened in a whistleblower lawsuit against SelectQuote, which claims the company engaged in misleading sales practices related to Medicare Advantage plans [1][3]. - The lawsuit, Pahlkotter v. SelectQuote Inc. et al., includes investors who purchased shares between September 9, 2020, and May 1, 2025, alleging that SelectQuote misrepresented its business model and regulatory risks [2][5]. Allegations of Misconduct - The complaint alleges that SelectQuote misrepresented its sales practices, claiming to provide "unbiased advice" while actually directing customers towards higher-commission plans and accepting illegal kickbacks [3][7]. - The DOJ's complaint indicates that from 2016 to at least 2021, SelectQuote received tens of millions of dollars in improper payments and discriminated against less profitable customers [3][7]. Market Reaction - Following the DOJ's involvement, SelectQuote's stock price fell nearly 20% in a single day, and shares have declined over 40% in the past six months due to investor concerns about legal exposure and reputational damage [4][5]. Investigative Actions - Hagens Berman, a shareholder rights firm, is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, transforming the situation into a serious federal matter [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [1][3]. Group 1: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives made false and misleading statements regarding the company's competitive position and financial guidance [3]. - Specifically, it is claimed that LifeMD's 2025 guidance was raised recklessly without properly accounting for increased customer acquisition costs, particularly in the RexMD segment and for obesity treatment drugs [3]. - As a result of these alleged misstatements, the company's business operations and prospects were deemed materially false and misleading [3]. Group 2: Financial Impact - On August 5, 2025, LifeMD reported its Q2 2025 financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous estimate of $268 to $275 million [4]. - Following this announcement, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [4]. Group 3: Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against LifeMD is October 27, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

Core Points - Rosen Law Firm is reminding purchasers of Snap Inc. securities from April 29, 2025, to August 5, 2025, about the October 20, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Snap securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 20, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that Snap's defendants misrepresented the company's advertising revenue and growth potential while downplaying macroeconomic instability [5]. - It is claimed that Snap's optimistic reports did not reflect the reality of its execution errors, leading to investor damages when the truth was revealed [5].

, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLPÂ (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Fortinet, Inc. ("Fortinet") (NASDAQ: FTNT) on behalf of those who purchased or otherwise acquired Fortinet common stock between November 8, 2024, and August 6, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is November 21, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:Â CLICK HERE Â TO SIGN UP FOR THE CASE Â OR GO TO:Â http ...

Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=170976&from=4Â CLASS PERIOD: May 7, 2025 to August 5, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, due to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be cut, leading to misleading positive statements about the company's business and prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Points - ClaimsFiler reminds investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Molina Healthcare, Inc. for the Class Period from February 5, 2025, to July 23, 2025 [1] - The lawsuit alleges that Molina Healthcare and certain executives failed to disclose material information, violating federal securities laws [3] - Following the company's second-quarter financial results announcement on July 23, 2025, which included an 8% year-over-year decrease in GAAP net income and a cut in full-year earnings guidance, Molina's share price dropped by 16.84% [4] Company Information - Molina Healthcare reported a GAAP net income of $4.75 per diluted share for Q2 2025, down from the previous year, and adjusted earnings expectations for the full year 2025 to be no less than $19.00 per diluted share due to challenging medical cost trends [4] - The case is officially titled Hindlemann v. Molina Healthcare, Inc., et al., No. 2:25-cv-09461 [5] Investor Resources - ClaimsFiler provides a platform for retail investors to recover funds from securities class action settlements, offering free registration, portfolio data uploads, and inquiries for case evaluations [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Dow Inc. securities between January 30, 2025, and July 23, 2025, about the upcoming lead plaintiff deadline of October 28, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Dow securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by October 28, 2025 [2]. - The lawsuit alleges that Dow made false and misleading statements regarding its ability to handle macroeconomic challenges and maintain financial flexibility, which ultimately misled investors about the company's true financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 alone [3].

NEW YORK and NEW ORLEANS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 18, 2025 to file lead plaintiff applications in a securities class action lawsuit against KBR, Inc. (NYSE: KBR), if they purchased or otherwise acquired the Company’s securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”). This action is pending in the United States Dist ...

Core Viewpoint - A securities class action lawsuit has been filed against Fluor Corporation for alleged misleading statements and failure to disclose significant cost increases and negative impacts on financial results during the Class Period from February 18, 2025, to July 31, 2025 [1][2]. Allegations of Misconduct - The complaint alleges that costs for the Gordie Howe International Bridge and Texas highway projects were increasing due to subcontractor design errors, price hikes, and scheduling delays [2]. - It is claimed that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on Fluor's business and financial results [2]. - The financial guidance provided by Fluor for fiscal year 2025 is alleged to be unreliable and overstated regarding the effectiveness of its risk mitigation strategy and the impact of economic uncertainty [2]. Lead Plaintiff Process - Fluor investors can seek to be appointed as a lead plaintiff representative by November 14, 2025, or may choose to remain absent from the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].